î
îŒ
ãã°ã€ã³
î
Inhibikase Therapeutics Inc
IKT1.604USD
-0.026-1.60%
ååŒæé ïŒETïŒ15åé
ãã®æ ªäŸ¡
2.38Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± Inhibikase Therapeutics Inc äŒæ¥å
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Companyâs multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Inhibikase Therapeutics Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãIKT
äŒç€ŸåInhibikase Therapeutics Inc
äžå Žæ¥Dec 23, 2020
æé«çµå¶è²¬ä»»è
ãCEOãIwicki (Mark T)
åŸæ¥å¡æ°15
蚌åžçš®é¡Ordinary Share
決ç®ææ«Dec 23
æ¬ç€Ÿæåšå°1000 N. West Street, Suite 1200
éœåžWILMINGTON
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·19801
é»è©±çªå·13022953800
ãŠã§ããµã€ãhttps://www.inhibikase.com/
äŒæ¥ã³ãŒãIKT
äžå Žæ¥Dec 23, 2020
æé«çµå¶è²¬ä»»è
ãCEOãIwicki (Mark T)
Inhibikase Therapeutics Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Roberto Bellini
Mr. Roberto Bellini
Independent Director
Independent Director
1.46M
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
-50.00%
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
638.25K
-40.00%
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
412.72K
-4.63%
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
Mr. David Canner, Ph.D.
Mr. David Canner, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Managing Director of LifeSci Advisors
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Roberto Bellini
Mr. Roberto Bellini
Independent Director
Independent Director
1.46M
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
-50.00%
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
638.25K
-40.00%
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
412.72K
-4.63%
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Thu, Feb 19
æŽæ°æå»: Thu, Feb 19
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Sands Capital Ventures LLC
9.86%
Soleus Capital Management, L.P.
8.24%
Fairmount Funds Management LLC
6.53%
Adar1 Capital Management LLC
6.11%
Trails Edge Capital Partners LP
4.68%
ä»ã®
64.58%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Sands Capital Ventures LLC
9.86%
Soleus Capital Management, L.P.
8.24%
Fairmount Funds Management LLC
6.53%
Adar1 Capital Management LLC
6.11%
Trails Edge Capital Partners LP
4.68%
ä»ã®
64.58%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Hedge Fund
47.69%
Investment Advisor
21.36%
Investment Advisor/Hedge Fund
10.56%
Corporation
4.83%
Private Equity
4.48%
Individual Investor
3.51%
Research Firm
0.42%
Bank and Trust
0.08%
Pension Fund
0.04%
ä»ã®
7.02%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Thu, Jan 1
æŽæ°æå»: Thu, Jan 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
122
64.55M
53.39%
+6.52M
2025Q3
110
54.77M
73.50%
+878.44K
2025Q2
87
62.36M
83.88%
+6.72M
2025Q1
82
60.21M
81.40%
+7.53M
2024Q4
61
58.78M
83.36%
+15.59M
2024Q3
38
1.99M
24.34%
-203.16K
2024Q2
42
2.13M
28.26%
+379.22K
2024Q1
47
1.51M
21.65%
-625.47K
2023Q4
49
1.53M
25.68%
-638.36K
2023Q3
54
2.02M
35.52%
-749.23K
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Sands Capital Ventures LLC
13.02M
10.77%
+2.07M
+18.89%
Nov 21, 2025
Soleus Capital Management, L.P.
6.33M
5.23%
--
--
Sep 30, 2025
Fairmount Funds Management LLC
6.13M
5.07%
--
--
Sep 30, 2025
Adar1 Capital Management LLC
5.25M
4.34%
+125.50K
+2.45%
Sep 30, 2025
Blackstone Alternative Asset Management, L.P.
2.64M
2.18%
--
--
Sep 30, 2025
SP IKT Holdings LLC
5.84M
4.83%
+5.84M
--
Oct 21, 2024
Perceptive Advisors LLC
5.42M
4.48%
-10.72K
-0.20%
Sep 30, 2025
Commodore Capital LP
5.40M
4.46%
--
--
Sep 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
æ¯ç0.02%
iShares Russell 2000 Value ETF
æ¯ç0.01%
ProShares Hedge Replication ETF
æ¯ç0%
iShares Russell 2000 ETF
æ¯ç0%
iShares Russell 2000 Growth ETF
æ¯ç0%
Global X Russell 2000 ETF
æ¯ç0%
Proshares Ultra Russell 2000
æ¯ç0%
ProShares UltraPro Russell2000
æ¯ç0%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Jun 29, 2023
Merger
6â1
Jun 29, 2023
Merger
6â1
Jun 29, 2023
Merger
6â1
Jun 29, 2023
Merger
6â1
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Jun 29, 2023
Merger
6â1
Jun 29, 2023
Merger
6â1
Jun 29, 2023
Merger
6â1
Jun 29, 2023
Merger
6â1
